These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7585011)

  • 21. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis.
    Li JP; Galvis ML; Gong F; Zhang X; Zcharia E; Metzger S; Vlodavsky I; Kisilevsky R; Lindahl U
    Proc Natl Acad Sci U S A; 2005 May; 102(18):6473-7. PubMed ID: 15843464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteoglycans and amyloid fibrillogenesis.
    Kisilevsky R; Fraser P
    Ciba Found Symp; 1996; 199():58-67; discussion 68-72, 90-103. PubMed ID: 8915604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide.
    Buée L; Ding W; Anderson JP; Narindrasorasak S; Kisilevsky R; Boyle NJ; Robakis NK; Delacourte A; Greenberg B; Fillit HM
    Brain Res; 1993 Nov; 627(2):199-204. PubMed ID: 8298962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Heparan sulphates, amyloidosis and neurodegeneration].
    Vera C; Alvarez-Orozco JA; Maiza A; Chantepie S; Chehin RN; Ouidja MO; Papy-Garcia D
    Rev Neurol; 2017 Nov; 65(10):457-468. PubMed ID: 29130469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerated resolution of AA amyloid in heparanase knockout mice is associated with matrix metalloproteases.
    Wang B; Tan YX; Jia J; Digre A; Zhang X; Vlodavsky I; Li JP
    PLoS One; 2012; 7(7):e39899. PubMed ID: 22808071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils.
    Nelson SR; Lyon M; Gallagher JT; Johnson EA; Pepys MB
    Biochem J; 1991 Apr; 275 ( Pt 1)(Pt 1):67-73. PubMed ID: 1902087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Qualitative and quantitative analysis.
    Snow AD; Kisilevsky R; Stephens C; Anastassiades T
    Lab Invest; 1987 Jun; 56(6):665-75. PubMed ID: 3599910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease.
    Narindrasorasak S; Altman RA; Gonzalez-DeWhitt P; Greenberg BD; Kisilevsky R
    Lab Invest; 1995 Mar; 72(3):272-82. PubMed ID: 7898047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein E and apolipoprotein A-1 knock-out mice readily develop amyloid A protein amyloidosis.
    Elliott-Bryant R; Cathcart ES
    Clin Immunol Immunopathol; 1997 Oct; 85(1):104-8. PubMed ID: 9325076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibronectin and basement membrane components in renal amyloid deposits in patients with primary and secondary amyloidosis.
    Westermark GT; Norling B; Westermark P
    Clin Exp Immunol; 1991 Oct; 86(1):150-6. PubMed ID: 1914228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of fibronectin in the development of experimental amyloidosis. Evidence of immunohistochemical codistribution and binding property with serum amyloid protein A.
    Kawahara E; Shiroo M; Nakanishi I; Migita S
    Am J Pathol; 1989 Jun; 134(6):1305-14. PubMed ID: 2757120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transmission of systemic AA amyloidosis in animals.
    Murakami T; Ishiguro N; Higuchi K
    Vet Pathol; 2014 Mar; 51(2):363-71. PubMed ID: 24280941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel glycosaminoglycan precursors as antiamyloid agents: Part IV.
    Kisilevsky R; Szarek WA; Ancsin J; Vohra R; Li Z; Marone S
    J Mol Neurosci; 2004; 24(1):167-72. PubMed ID: 15314266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can deposition of amyloid be prevented in Alzheimer's disease?
    Kisilevsky R
    Ann N Y Acad Sci; 1997 Sep; 826():117-27. PubMed ID: 9329685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications.
    Kisilevsky R; Ancsin JB; Szarek WA; Petanceska S
    Amyloid; 2007 Mar; 14(1):21-32. PubMed ID: 17453622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch.
    Elimova E; Kisilevsky R; Ancsin JB
    FASEB J; 2009 Oct; 23(10):3436-48. PubMed ID: 19549924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histological study of experimental murine AA amyloidosis.
    Kuroiwa M; Aoki K; Izumiyama N
    J Electron Microsc (Tokyo); 2003; 52(4):407-13. PubMed ID: 14599103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What role(s) may extracellular matrix, particularly heparan sulfate, play in amyloid of Alzheimer's disease.
    Benditt EP
    Neurobiol Aging; 1989; 10(5):506; discussion 510-2. PubMed ID: 2530463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of glycosaminoglycans in human renal and splenic secondary AA amyloid fibril preparations.
    Stenstad T; Magnus JH; Kolset SO; Husby G
    Scand J Rheumatol; 1991; 20(1):1-7. PubMed ID: 2011711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental AA-amyloidosis in mice is inhibited by treatment with the anti-rheumatic drug tenidap.
    Husebekk A; Stenstad T
    Scand J Immunol; 1996 May; 43(5):551-5. PubMed ID: 8633214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.